Other News To Note
• Endocyte Inc., of West Lafayette, Ind., and Merck & Co. Inc., of Whitehouse Station, N.J., said the European Medicines Agency accepted for review a marketing authorization application for vintafolide (MK-8109/EC145) and the diagnostic imaging agent etarfolatide (EC20), which are in development for targeted treatment of folate-receptor-positive, platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter